Diagnosis & Differentiation
Pleural Mesothelioma: Advances in Blood and Pleural Biomarkers
Journal of Clinical Medicine 2023 November 9 [Link] Claudio Sorino, Michele Mondoni, Giampietro Marchetti, Sergio Agati, Riccardo Inchingolo, Federico Mei, Sara Flamini, Filippo Lococo, David Feller-Kopman Abstract Pleural mesothelioma (PM) is a type of cancer that is highly related to exposure to asbestos fibers. It shows aggressive behavior, and the current therapeutic approaches are usually…
Read MoreSalvage pleurectomy/decortication following immunotherapy for malignant pleural mesothelioma
Interdisciplinary Cardiovascular and Thoracic Surgery 2023 November 15 [Link] Masaru Takenaka, Koji Kuroda, Katsuma Yoshimatsu, Masataka Mori, Masatoshi Kanayama, Akihiro Taira, Taiji Kuwata, Fumihiro Tanaka Abstract Salvage surgery following immunotherapy is a promising treatment option for advanced malignant tumour. However, only a few cases of salvage surgery for malignant pleural mesothelioma (MPM) have been reported.…
Read MoreTreatment with tumor-treating fields (TTFields) suppresses intercellular tunneling nanotube formation in vitro and upregulates immuno-oncologic biomarkers in vivo in malignant mesothelioma
eLife 2023 November 13 [Link] Akshat Sarkari, Sophie Korenfeld, Karina Deniz, Katherine Ladner, Phillip Wong, Sanyukta Padmanabhan, Rachel I Vogel, Laura A Sherer, Naomi Courtemanche, Clifford Steer, Kerem Wainer-Katsir, Emil Lou Abstract Disruption of intercellular communication within tumors is emerging as a novel potential strategy for cancer-directed therapy. Tumor-Treating Fields (TTFields) therapy is a treatment…
Read MoreA data mining technique for detecting malignant mesothelioma cancer using multiple regression analysis
Open Life Sciences 2023 November 3 [Link] Abdulla Mousa Falah Alali, Dhyaram Lakshmi Padmaja, Mukesh Soni, Muhammad Attique Khan, Faheem Khan, Isaac Ofori Abstract Lung cancer is a substantial health issue globally, and it is one of the main causes of mortality. Malignant mesothelioma (MM) is a common kind of lung cancer. The majority of…
Read MoreCo-existing pericardial and pleural malignant mesothelioma responding well to nedaplatin and pemetrexed: a case report
AME Case Reports 2023 August 3 [Link] Mindan Wu, Zhixuan Li, Junfu Cai, Xianyang Zhong, Wenchuan Zheng, Shuhan Wu, Maohuang Lin, Qichuan Zhang Abstract Background: Malignant mesothelioma (MM) is a rare cancer with poor prognosis. It is less common that two serosal cavities are involved when the patient seeks medical attention firstly. The current first-line…
Read MoreContribution of BAP1 loss and p16 (CDKN2A) deletion analysis to the definitive diagnosis of mesothelioma in effusion cytology
European Review for Medical and Pharmacological Sciences 2023 October [Link] G Aydogdu, S Özekinci Abstract Objective: The cytological diagnosis of mesothelioma is a controversial issue, and definitive diagnosis often requires ancillary tests. The aim of this study was to investigate the contribution of BRCA1-associated protein (1) (BAP1) loss and p16 (CDKN2A) homozygous deletion (HD) on…
Read MoreDeletions of CDKN2A and MTAP Detected by Copy-Number Variation Array Are Associated with Loss of p16 and MTAP Protein in Pleural Mesothelioma
Cancers 2023 October 13 [Link] Bart Vrugt, Michaela B Kirschner, Mayura Meerang, Kathrin Oehl, Ulrich Wagner, Alex Soltermann, Holger Moch, Isabelle Opitz, Peter J Wild Abstract CDKN2A deletion is a common alteration in pleural mesothelioma (PM) and frequently associated with co-deletion of MTAP. Since the standard detection method for CDKN2A deletion and FISH analysis is…
Read MoreThe prognostic value of F18 Fluorothymidine positron emission tomography for assessing the response of malignant pleural mesothelioma to chemotherapy – A prospective cohort study
Journal of Medical Imaging and Radiation Oncology 2023 October 29 [Link] Isaac J May, Anna K Nowak, Roslyn J Francis, Martin A Ebert, Satvinder S Dhaliwal Abstract Introduction: Malignant pleural mesothelioma is difficult to prognosticate. F18-Fluorodeoxyglucose positron emission tomography (FDG PET) shows promise for response assessment but is confounded by talc pleurodesis. F18-Fluorothymidine (FLT) PET…
Read MorePD-1-expressing macrophages and CD8 T cells are independent predictors of clinical benefit from PD-1 inhibition in advanced mesothelioma
Journal for Immunotherapy for Cancer 2023 October [Link] Krisztian Homicsko, Panagiota Zygoura, Maxim Norkin, Stephanie Tissot, Nicholas Shakarishvili, Sanjay Popat, Alessandra Curioni-Fontecedro, Mary O’Brien, Anthony Pope, Riyaz Shah, Patricia Fisher, James Spicer, Amy Roy, David Gilligan, Sylvie Rusakiewicz, Ekaterina Fortis, Nesa Marti, Roswitha Kammler, Stephen P Finn, Georges Coukos, Urania Dafni, Solange Peters, Rolf A…
Read MoreClaudin-4 immunocytochemistry is specific and sensitive for the diagnosis of malignant carcinomatous effusions: Results from a pilot study
Diagnostic Cytopathology 2023 October 13 [Link] Vanlal Hruaii, Balamurugan Thirunavukkarasu, Vindhya Prabha, Sandeep Mathur, Venkateswaran K Iyer, Aruna Nambirajan, Deepali Jain Abstract Background: Claudin-4, a tight junction associated protein expressed in epithelial cells, is purported as a highly specific and sensitive marker for epithelial malignancies. Our aim was to assess the sensitivity, specificity and real-time…
Read More